Smarter Molecules.
Targeted Delivery.
Faster to Patients.
Onconox is redefining medicine development, creating safer, more effective therapies for patients with cancer and neurodegeneration.
Partnerships & Ecosystem
We collaborate with world-class partners in:
This partner-enabled model ensures capital efficiency, scalability, and rapid execution.
Drug delivery devices
enabling inhaled, intranasal, and direct-to-tumor routes
CROs & CDMOs
advancing programs through equity-for-service models
AI discovery
accelerating asset selection and optimization
Patient Impact
At Onconox, patients are at the heart of everything we do. Our therapies are designed to:
• Improve survival and quality of life
• Minimize treatment burden and side effects
• Provide new options for those with limited alternatives
Every program we advance is guided by one principle: therapies must be effective, tolerable, and accessible to the patients who need them most.
Our Lead Program: OCN001
OCN001 is the first program to emerge from our BIG Platform — an inhaled radiosensitizer in development for non-small cell lung cancer (NSCLC).
Delivered directly to the lungs, OCN001 is designed to:
• Enhance the effectiveness of radiotherapy
• Minimize systemic toxicity
• Offer a low-burden, patient-friendly treatment option
OCN001 demonstrates the potential of our BIG Platform and lays the foundation for future programs that will extend into neurodegenerative conditions and other solid tumors.
AI at the Core
We embed AI into every stage of development — from prioritizing assets to predicting combinations and optimizing delivery. This ensures faster decision-making, reduced risk, and smarter therapies for patients.
Pipeline Snapshot
Program | Indication | Delivery | Stage |
|---|---|---|---|
OCN001 | NSCLC (Stage I & III) | Inhaled | IND-Enabling |
OCN002 | NSCLC & SCLC | Inhaled | Preclinical |
OCN003 | Glioblastoma (GBM) | Intranasal | Preclinical |
OCN004 | Solid Tumors | Intratumoral
| Discovery |
OCN005 | Parkinsons Disease
| Intranasal | Discovery |
Pipeline Snapshot
At Onconox
The Problems
We Solve
Unmet Needs in High-Burden Diseases
Patients with cancer and neurodegenerative conditions continue to face limited, often inadequate treatment options, making these high-burden diseases some of the most underserved in modern medicine.
Systemic Toxicity & Patient
Burden
Today’s systemic therapies expose the whole body to treatment, driving unnecessary toxicity, poor tolerability, and reduced quality of life for the patients who can least afford it.
Inefficient & Risk-Prone Development
Drug development remains slow, costly, and uncertain, delaying access to new treatments while early-stage programs fail at unacceptably high rates.
Challenge
Our BIG Platform
Our BIG Platform is built around a single small molecule with decades of clinical safety data. By intelligently reformulating and repurposing this molecule, we unlock new therapeutic potential across oncology and neurodegeneration.
The BIG Platform focuses on three precision delivery routes:
• Inhaled Delivery — radiosensitization and anti-cancer therapy
• Intranasal Delivery — brain-targeted therapies for glioblastoma and neurodegeneration
• Direct-to-Tumor Delivery — localized radiosensitization and sustained release for solid tumors
Pipeline Snapshot
Program | Indication | Delivery | Stage |
|---|---|---|---|
OCN001 | NSCLC (Stage I & III) | Inhaled | IND-Enabling |
OCN002 | NSCLC & SCLC | Inhaled | Preclinical |
OCN003 | Glioblastoma (GBM) | Intranasal | Preclinical |
OCN004 | Solid Tumors | Intratumoral
| Discovery |
OCN005 | Parkinsons Disease
| Intranasal | Discovery |
For Investors
Onconox is built for both innovation and capital efficiency. Our approach reduces risk, shortens timelines, and provides multiple shots on goal across oncology and CNS diseases.
With strong regulatory alignment and differentiated delivery technologies, we are creating therapies that are smarter for the system and better for the patient.
